Skip to content
Search AI Powered

Latest Stories

Covid: Thousands in UK receive new antiviral treatment at home

Covid: Thousands in UK receive new antiviral treatment at home

THE NHS has started providing a new antiviral treatment against Covid for high-risk patients at home that improves symptoms “within hours”, the health service said in a statement. 

Known as Paxlovid, has been given to more than 6,000 patients already – with over 1,400 patients benefitting in the last seven days alone. It is expected to cut hospitalisation and deaths by 88 per cent. 


The NHS has given 'game-changing' covid treatments to more than 32,000 patients since December. 

According to the statement, the treatment stops the virus from multiplying in cells and therefore prevents the virus from multiplying in the body.

Professor Stephen Powis, NHS national medical director, said: “It’s fantastic that since launching the latest antiviral treatment Paxlovid just over a month ago, thousands of our most vulnerable patients have already had access to this latest cutting-edge, life-saving treatment.

“Antivirals are another weapon in our arsenal to reduce hospital admissions and fatalities amongst patients at highest risk of becoming seriously ill from Covid-19 and needing hospitalisation — each and every person treated with the new drugs is a testament to how the NHS is doing everything possible to protect those who are at most risk."

It will be up to clinicians to decide on a case-by-case basis whether this treatment or another Covid-19 medicine, is the best choice for their patients. People who are eligible for Paxlovid will be sent the tests to keep at home in case they develop symptoms, the NHS said.

Health secretary Sajid Javid said: “We have secured more antivirals per head than any other country in Europe - almost five million doses for NHS patients. Both of our groundbreaking antivirals – molnupiravir and Paxlovid – are available to those most vulnerable to the virus directly through the NHS, and it’s fantastic to see 32,000 patients reaping the benefits.

“For anyone not in this high-risk group, if you’re aged 50 and over or 18 to 49 with an underlying health condition and test positive, you can sign up to the PANORAMIC study to potentially access this treatment too.”

“Although I initially declined Paxlovid because I didn’t feel too bad. I had initially felt fine, just a bit tired, but two days in I had an extremely sore throat, to the point where I couldn’t swallow or talk, and I could barely walk," said Helen West, 56, from Walderslade, Kent, who received Paxlovid.

“The process was so quick and efficient. Within six hours of taking the first tablet, I felt a very slight improvement. After four days, I was back to work. Covid hit me hard but Paxlovid really made a positive difference to my recovery.”

Another Paxlovid patient, Cathy Merry from Duffield near Derby, said: “Having these treatments available is just brilliant and we are so lucky to have them for free on the NHS. The hospital staff have always been brilliant, but to deal with this so efficiently is absolutely unbelievably good care.

“I lived in the US and we are so lucky to have the NHS and the brilliant care they give to us all.”

More For You

Indian court upholds Adani's Mumbai slum revamp contract

Gautam Adani

Indian court upholds Adani's Mumbai slum revamp contract

AN Indian court on Friday (20) dismissed a petition challenging the award of a contract to Adani Group to revamp one of Asia's largest slums in Mumbai, clearing one of the main legal challenges to the ambitious project.

The group led by billionaire Gautam Adani won a $619 million (£494.31m) bid in 2023 to convert the Dharavi slum into a modern city hub, but Dubai-based SecLink Technologies Corporation, winner of a previous tender for the slum revamp, challenged the award of the contract to Adani in a petition in the Bombay High Court in July 2023.

Keep ReadingShow less
October declared Hindu Heritage Month in Ohio, US

The Hindu American Foundation (HAF) welcomed the bill’s passage. (Representational image: iStock)

October declared Hindu Heritage Month in Ohio, US

THE OHIO State House and Senate in the US have passed a bill designating October as Hindu Heritage Month.

State senator Niraj Antani, who led the effort, expressed his satisfaction with the bill's passage.

Keep ReadingShow less
Kyle Clifford

During the hearing, Clifford denied all the charges except for the rape charge, which was added to the indictment at the session. (Photo: Hertfordshire Police /Handout via REUTERS)

Man pleads not guilty to murder of BBC presenter's family

A 26-year-old man has pleaded not guilty to charges of murdering the wife and two daughters of BBC sports commentator John Hunt in a crossbow and knife attack.

Kyle Clifford, who also faces charges of rape, appeared via video link at Cambridge Crown Court on Thursday.

Keep ReadingShow less
Peter-Mandelson-Getty

Mandelson, a prominent ally of former prime minister Tony Blair, was instrumental in rebranding the Labour Party in the 1990s. (Photo: Getty Images)

Peter Mandelson to be new US ambassador

VETERAN Labour politician Peter Mandelson has been selected to become the UK's new ambassador to the United States, according to media reports on Thursday. An official announcement is expected on Friday (20).

Mandelson, 71, is set to take up the post in late January, coinciding with US president-elect Donald Trump’s return to the White House, the reports stated. This marks the first time in decades that a political appointee, rather than a seasoned diplomat, will hold the position.

Keep ReadingShow less
Kite-making picks up in Gujarat ahead of harvest festival

Kite-making picks up in Gujarat ahead of harvest festival


HUDDLED over piles of colourful paper, Mohammad Yunus is one among thousands of workers in India's western state of Gujarat who make kites by hand that are used during a major harvest festival.

People in Gujarat celebrate Uttarayan, a Hindu festival in mid-January that celebrates the end of winter by flying kites held by glass-coated or plastic strings.

Keep ReadingShow less